Tag: short-acting insulin market outlook

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Short-Acting Insulin Market Value Growth And Long-Term Outlook

The short-acting insulin market size has demonstrated robust growth in recent years. It is anticipated to increase from $11.54 billion in 2025 to $12.14 billion in 2026, recording a compound annual growth rate (CAGR) of 5.3%. Historically, this expansion has been driven by the elevated prevalence of diabetes, the extensive adoption of insulin therapy, hospital-based management of diabetes, the broadening of insulin access programs, and improved rates of diabetes diagnosis.

The short-acting insulin market size is projected to experience robust expansion over the coming years. It will grow to $14.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. This anticipated increase during the forecast period is due to factors such as the rising occurrence of type 2 diabetes, growing reliance on insulin, the expansion of home-based diabetes management, advancements in insulin delivery methods, and an escalating need for fast-acting insulin. Key developments expected in the forecast period encompass a growing need for post-meal blood glucose management, increased utilization of rapid-acting insulin analogues, wider acceptance of pre-filled insulin pens, the broadening of intensive insulin therapy protocols, and a heightened emphasis on precise glycemic control.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=79113975&type=smp&name=Short-Acting%20Insulin%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Short-Acting Insulin Market Demand Drivers: What’s Powering Industry Growth?

The growing incidence of type 1 diabetes is projected to propel expansion in the short-acting insulin market moving ahead. Type 1 diabetes is characterized as an autoimmune disorder in which the body’s immune system attacks and eliminates insulin-producing cells, necessitating continuous insulin treatment. The escalation in Type 1 diabetes cases stems from genetic predispositions, environmental factors, and an uptick in autoimmune conditions. Short-acting insulin aids in the management of type 1 diabetes by offering swift regulation of blood sugar and emulating the body’s natural insulin functions. As an illustration, in December 2023, data from Diabetes Australia, an Australian organization dedicated to diabetes awareness, indicated that around 134,000 Australians had Type 1 diabetes in 2022. This number subsequently rose to 135,423 by 2023. Consequently, the rising occurrence of type 1 diabetes is fostering the expansion of the short-acting insulin market.

Short-Acting Insulin Market Segmentation And Category Overview

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Short-Acting Insulin Market Innovation Trends: What Developments Are Reshaping The Industry?

Leading companies within the short-acting insulin market are prioritizing groundbreaking products, specifically interchangeable rapid-acting insulin biologic, to enhance patients’ glycemic control and provide versatile substitution possibilities. An interchangeable rapid-acting insulin biologic is defined as a biologically derived insulin formulation designed to quickly reduce blood glucose levels post-meals. It has regulatory approval for direct substitution with an equivalent insulin product, eliminating the need for a new prescription, thereby facilitating adaptable diabetes management and maintaining stable glycemic control. For instance, in July 2025, Biocon Biologics, a biosimilars company headquartered in both India and the U.S., secured FDA clearance for Kirsty (insulin aspart xjhz), marking it as the inaugural and sole interchangeable rapid-acting insulin aspart available in the United States. Kirsty functions as a biosimilar to NovoLog (insulin aspart), supported by clinical and analytical data that confirm its equivalence in terms of safety, efficacy, purity, and potency. This product is supplied as a 100 units/mL formulation, offered both in a single-patient-use prefilled pen for subcutaneous administration and a multi-dose vial suitable for both subcutaneous and intravenous use, with the objective of enhancing glycemic control for adults and children diagnosed with diabetes mellitus.

Short-Acting Insulin Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

View The Full Short-Acting Insulin Market Report:

https://thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Short-Acting Insulin Market Largest Region By Revenue And Market Share

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Short-Acting Insulin Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The short-acting insulin market has experienced robust expansion over the last few years, advancing from $11.54 billion in 2025 to a projected $12.14 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.3%. This upward trajectory during the historical period was driven by a high prevalence of diabetes, the widespread adoption of insulin therapy, hospital-centered diabetes management, the expansion of insulin access initiatives, and enhanced rates of diabetes diagnosis.

The market for short-acting insulin is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $14.87 billion, driven by a compound annual growth rate (CAGR) of 5.2%. This forecasted growth is largely fueled by a higher prevalence of type 2 diabetes, growing reliance on insulin, an uptick in home-based diabetes management, advances in insulin delivery systems, and a stronger preference for fast-acting insulin options. Among the key developments shaping this period are an escalating need for controlling blood sugar after meals, broader use of rapid-acting insulin analogues, wider uptake of pre-filled insulin pens, more frequent adoption of intensive insulin therapy protocols, and a heightened emphasis on achieving strict glycemic targets.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Short-Acting Insulin Market Expansion Drivers: What Is Shaping Future Growth?

The upward trend in type 1 diabetes cases is anticipated to propel the expansion of the short-acting insulin market in the coming years. Type 1 diabetes is an autoimmune disorder in which the body attacks its own insulin-producing cells, making lifelong insulin treatment essential. This condition is becoming more common due to genetic predispositions, environmental factors, and a rise in autoimmune diseases. Short-acting insulin addresses the needs of type 1 diabetes by offering swift blood glucose regulation and simulating the body’s natural insulin secretion. As an illustration, Diabetes Australia, an Australian organization dedicated to diabetes awareness, reported that in December 2023, around 134,000 Australians had type 1 diabetes in 2022, a number that climbed to 135,423 by 2023. Consequently, the growing incidence of type 1 diabetes is fueling the short-acting insulin market’s growth.

Short-Acting Insulin Market Segment Analysis And Revenue Opportunities

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Short-Acting Insulin Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Major players in the short-acting insulin market are placing increased emphasis on the development of cutting-edge products, specifically interchangeable rapid-acting insulin biologics, which are designed to improve glycemic control and give diabetic patients greater flexibility in treatment substitution. An interchangeable rapid-acting insulin biologic is a biologically-based insulin formulation that rapidly reduces blood glucose levels after meals, having received regulatory approval to be swapped for a comparable insulin product without the need for a fresh prescription, thereby offering adaptable diabetes care and ensuring steady glycemic management. A notable example occurred in July 2025, when Biocon Biologics—a biosimilars company based in the United States but headquartered in India and the U.S.—obtained FDA approval for Kirsty (insulin aspart xjhz), which stands as the first and only interchangeable rapid-acting insulin aspart available in the United States. Kirsty functions as a biosimilar to NovoLog (insulin aspart), with clinical and analytical evidence showing no meaningful differences in safety, efficacy, purity, or potency. This product comes in a 100 units/mL formulation, provided as a single-patient-use prefilled pen for subcutaneous injection and as a multi-dose vial suitable for both subcutaneous and intravenous administration, with the goal of enhancing glycemic control in both adults and children suffering from diabetes mellitus.

Short-Acting Insulin Market Leading Players Shaping Industry Direction

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Access The Complete Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Short-Acting Insulin Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Short-Acting Insulin Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The short-acting insulin market has experienced robust expansion over the last few years, advancing from $11.54 billion in 2025 to a projected $12.14 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.3%. This upward trajectory during the historical period was driven by a high prevalence of diabetes, the widespread adoption of insulin therapy, hospital-centered diabetes management, the expansion of insulin access initiatives, and enhanced rates of diabetes diagnosis.

The market for short-acting insulin is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $14.87 billion, driven by a compound annual growth rate (CAGR) of 5.2%. This forecasted growth is largely fueled by a higher prevalence of type 2 diabetes, growing reliance on insulin, an uptick in home-based diabetes management, advances in insulin delivery systems, and a stronger preference for fast-acting insulin options. Among the key developments shaping this period are an escalating need for controlling blood sugar after meals, broader use of rapid-acting insulin analogues, wider uptake of pre-filled insulin pens, more frequent adoption of intensive insulin therapy protocols, and a heightened emphasis on achieving strict glycemic targets.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Short-Acting Insulin Market Expansion Drivers: What Is Shaping Future Growth?

The upward trend in type 1 diabetes cases is anticipated to propel the expansion of the short-acting insulin market in the coming years. Type 1 diabetes is an autoimmune disorder in which the body attacks its own insulin-producing cells, making lifelong insulin treatment essential. This condition is becoming more common due to genetic predispositions, environmental factors, and a rise in autoimmune diseases. Short-acting insulin addresses the needs of type 1 diabetes by offering swift blood glucose regulation and simulating the body’s natural insulin secretion. As an illustration, Diabetes Australia, an Australian organization dedicated to diabetes awareness, reported that in December 2023, around 134,000 Australians had type 1 diabetes in 2022, a number that climbed to 135,423 by 2023. Consequently, the growing incidence of type 1 diabetes is fueling the short-acting insulin market’s growth.

Short-Acting Insulin Market Segment Analysis And Revenue Opportunities

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Short-Acting Insulin Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Major players in the short-acting insulin market are placing increased emphasis on the development of cutting-edge products, specifically interchangeable rapid-acting insulin biologics, which are designed to improve glycemic control and give diabetic patients greater flexibility in treatment substitution. An interchangeable rapid-acting insulin biologic is a biologically-based insulin formulation that rapidly reduces blood glucose levels after meals, having received regulatory approval to be swapped for a comparable insulin product without the need for a fresh prescription, thereby offering adaptable diabetes care and ensuring steady glycemic management. A notable example occurred in July 2025, when Biocon Biologics—a biosimilars company based in the United States but headquartered in India and the U.S.—obtained FDA approval for Kirsty (insulin aspart xjhz), which stands as the first and only interchangeable rapid-acting insulin aspart available in the United States. Kirsty functions as a biosimilar to NovoLog (insulin aspart), with clinical and analytical evidence showing no meaningful differences in safety, efficacy, purity, or potency. This product comes in a 100 units/mL formulation, provided as a single-patient-use prefilled pen for subcutaneous injection and as a multi-dose vial suitable for both subcutaneous and intravenous administration, with the goal of enhancing glycemic control in both adults and children suffering from diabetes mellitus.

Short-Acting Insulin Market Leading Players Shaping Industry Direction

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Access The Complete Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Short-Acting Insulin Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Short-Acting Insulin Market From 2026 To 2030?

The short-acting insulin market has shown strong growth in recent years. It is projected to increase from $11.54 billion in 2025 to $12.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.3%. The historical expansion of this market can be attributed to factors such as the high prevalence of diabetes, widespread adoption of insulin therapy, hospital-based diabetes management, the expansion of insulin access programs, and improved diabetes diagnosis rates.

The short-acting insulin market is projected to experience robust expansion over the coming years. Its valuation will reach $14.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. This anticipated increase can be attributed to several factors such as the growing prevalence of type 2 diabetes, greater reliance on insulin, the rise of home-based diabetes management, advancements in insulin delivery methods, and an escalating need for fast-acting insulin. Key developments expected during this period involve an increasing call for post-meal blood glucose regulation, wider application of rapid-acting insulin analogues, more widespread adoption of pre-filled insulin pens, the expansion of intensive insulin therapy protocols, and a heightened emphasis on precise glycemic control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

What Market Drivers Are Helping Shape The Short-Acting Insulin Market Expansion?

The expansion of the short-acting insulin market is expected to be fueled by the growing occurrence of type 1 diabetes. Type 1 diabetes, an autoimmune condition, involves the body’s destruction of insulin-producing cells, making lifelong insulin therapy essential. The rising frequency of Type 1 diabetes is attributed to genetic factors, environmental triggers, and an increase in autoimmune disorders. Short-acting insulin plays a vital role in managing type 1 diabetes by ensuring swift blood sugar regulation and mimicking the natural insulin process. For instance, in December 2023, according to Diabetes Australia, an Australia-based organization focused on diabetes awareness, around 134,000 Australians were living with Type 1 diabetes in 2022, with this figure climbing to 135,423 in 2023. Therefore, the increasing prevalence of type 1 diabetes is a key driver for the growth of the short-acting insulin market.

Which Segment Divisions Form The Structure Of The Short-Acting Insulin Market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Trends Are Affecting The Short-Acting Insulin Market Dynamics?

Leading companies in the short-acting insulin market are concentrating on advanced products, like interchangeable rapid-acting insulin biologics, to improve glycemic regulation and offer versatile substitution choices for diabetic patients. An interchangeable rapid-acting insulin biologic refers to a biologically derived insulin variant that quickly lowers blood glucose levels after eating and has received regulatory authorization to be exchanged for another equivalent insulin product without requiring a new prescription, thus providing adaptability in diabetes management and ensuring consistent glycemic control. For instance, in July 2025, Biocon Biologics, a US-based biosimilars firm based in India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz), marking it as the first and only interchangeable rapid-acting insulin aspart in the United States. Kirsty is a biosimilar to NovoLog (insulin aspart), supported by clinical and analytical data that shows no meaningful distinctions in safety, efficacy, purity, or potency. It is provided as a 100 units/mL formulation, available in both a single-patient-use prefilled pen (for subcutaneous use) and a multi-dose vial (for both subcutaneous and intravenous administration), with the goal of enhancing glycemic control in adults and children afflicted with diabetes mellitus.

Which Companies Form The Competitive Landscape Of The Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Access The Complete Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Region Stands As The Largest Contributor To The Short-Acting Insulin Market?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Short-Acting Insulin Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2026, By The Business Research Company

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Instant Tea Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/instant-tea-premix-global-market-report

Technical Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/technical-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Short-Acting Insulin Market Projected To Reach By 2030?

The short-acting insulin market has witnessed significant expansion in recent years. Its valuation is projected to increase from $11.54 billion in 2025 to $12.14 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.3%. Historically, this growth has been influenced by the high prevalence of diabetes, widespread insulin therapy adoption, hospital-based diabetes management, expansion of insulin access programs, and improved diabetes diagnosis rates.

The short-acting insulin market is projected to experience substantial expansion in the coming years. By 2030, its valuation is predicted to reach $14.87 billion, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expansion during the projected timeframe is primarily driven by factors such as the increasing prevalence of type 2 diabetes, a growing reliance on insulin, the proliferation of home-based diabetes management, advancements in insulin delivery systems, and a heightened need for fast-acting insulin. Key developments anticipated within this period encompass an escalating requirement for managing post-meal blood glucose, the wider application of rapid-acting insulin analogues, increased preference for pre-filled insulin pens, the broadening of intensive insulin therapy protocols, and a stronger emphasis on precise glycemic control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Major Drivers Are Influencing The Expansion Of The Short-Acting Insulin Market?

The rising occurrence of type 1 diabetes is anticipated to propel the expansion of the short-acting insulin market in the future. This autoimmune disorder involves the body’s destruction of insulin-producing cells, necessitating continuous insulin treatment. Its growing incidence is influenced by genetic predispositions, environmental factors, and an uptick in autoimmune conditions. Short-acting insulin assists in managing type 1 diabetes through quick regulation of blood sugar and by imitating the body’s natural insulin function. For example, as reported in December 2023 by Diabetes Australia, an organization based in Australia dedicated to raising diabetes awareness, roughly 134,000 Australians had Type 1 diabetes in 2022. By 2023, this number had climbed to 135,423. Consequently, the expanding presence of type 1 diabetes is a significant force behind the growth of the short-acting insulin market.

What Are The Key Segment Divisions In The Short-Acting Insulin Market Segment Structure?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Trends Are Transforming The Short-Acting Insulin Market?

Leading companies active in the short-acting insulin market are concentrating on innovative products, such as interchangeable rapid-acting insulin biologics, to improve glycemic management and provide flexible substitution options for patients with diabetes. An interchangeable rapid-acting insulin biologic refers to a biologically derived insulin formulation designed to quickly reduce blood glucose levels following meals, which has received regulatory approval to be substituted for another equivalent insulin product without the need for a new prescription, thereby offering versatility in diabetes care and maintaining consistent glycemic control. For instance, in July 2025, Biocon Biologics, a US-based biosimilars company with headquarters in India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz), which is the first and only interchangeable rapid-acting insulin aspart available in the United States. Kirsty is recognized as a biosimilar to NovoLog (insulin aspart), with clinical and analytical data confirming no significant differences in terms of safety, efficacy, purity, and potency. It is supplied as a 100 units/mL formulation in both a single-patient-use prefilled pen (for subcutaneous use) and a multi-dose vial (for both subcutaneous and intravenous administration), aiming to enhance glycemic control in adults and children affected by diabetes mellitus.

Which Organizations Are Engaged In The Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Get The Full Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Where Is The Short-Acting Insulin Market Primarily Concentrated By Region?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Short-Acting Insulin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2026, By The Business Research Company

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Instant Tea Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/instant-tea-premix-global-market-report

Technical Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/technical-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Short-Acting Insulin Market Projected To Reach By 2030?

The short-acting insulin market has witnessed significant expansion in recent years. Its valuation is projected to increase from $11.54 billion in 2025 to $12.14 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.3%. Historically, this growth has been influenced by the high prevalence of diabetes, widespread insulin therapy adoption, hospital-based diabetes management, expansion of insulin access programs, and improved diabetes diagnosis rates.

The short-acting insulin market is projected to experience substantial expansion in the coming years. By 2030, its valuation is predicted to reach $14.87 billion, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expansion during the projected timeframe is primarily driven by factors such as the increasing prevalence of type 2 diabetes, a growing reliance on insulin, the proliferation of home-based diabetes management, advancements in insulin delivery systems, and a heightened need for fast-acting insulin. Key developments anticipated within this period encompass an escalating requirement for managing post-meal blood glucose, the wider application of rapid-acting insulin analogues, increased preference for pre-filled insulin pens, the broadening of intensive insulin therapy protocols, and a stronger emphasis on precise glycemic control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Major Drivers Are Influencing The Expansion Of The Short-Acting Insulin Market?

The rising occurrence of type 1 diabetes is anticipated to propel the expansion of the short-acting insulin market in the future. This autoimmune disorder involves the body’s destruction of insulin-producing cells, necessitating continuous insulin treatment. Its growing incidence is influenced by genetic predispositions, environmental factors, and an uptick in autoimmune conditions. Short-acting insulin assists in managing type 1 diabetes through quick regulation of blood sugar and by imitating the body’s natural insulin function. For example, as reported in December 2023 by Diabetes Australia, an organization based in Australia dedicated to raising diabetes awareness, roughly 134,000 Australians had Type 1 diabetes in 2022. By 2023, this number had climbed to 135,423. Consequently, the expanding presence of type 1 diabetes is a significant force behind the growth of the short-acting insulin market.

What Are The Key Segment Divisions In The Short-Acting Insulin Market Segment Structure?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Trends Are Transforming The Short-Acting Insulin Market?

Leading companies active in the short-acting insulin market are concentrating on innovative products, such as interchangeable rapid-acting insulin biologics, to improve glycemic management and provide flexible substitution options for patients with diabetes. An interchangeable rapid-acting insulin biologic refers to a biologically derived insulin formulation designed to quickly reduce blood glucose levels following meals, which has received regulatory approval to be substituted for another equivalent insulin product without the need for a new prescription, thereby offering versatility in diabetes care and maintaining consistent glycemic control. For instance, in July 2025, Biocon Biologics, a US-based biosimilars company with headquarters in India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz), which is the first and only interchangeable rapid-acting insulin aspart available in the United States. Kirsty is recognized as a biosimilar to NovoLog (insulin aspart), with clinical and analytical data confirming no significant differences in terms of safety, efficacy, purity, and potency. It is supplied as a 100 units/mL formulation in both a single-patient-use prefilled pen (for subcutaneous use) and a multi-dose vial (for both subcutaneous and intravenous administration), aiming to enhance glycemic control in adults and children affected by diabetes mellitus.

Which Organizations Are Engaged In The Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Get The Full Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Where Is The Short-Acting Insulin Market Primarily Concentrated By Region?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Short-Acting Insulin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2026, By The Business Research Company

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Instant Tea Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/instant-tea-premix-global-market-report

Technical Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/technical-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Short-Acting Insulin Market At The End Of The 2026–2030 Forecast Period?

The short-acting insulin market has experienced substantial growth in recent years. This market is projected to expand from $11.54 billion in 2025 to $12.14 billion in 2026, at a compound annual growth rate (CAGR) of 5.3%. Historically, this growth can be attributed to the high prevalence of diabetes, widespread adoption of insulin therapy, hospital-based diabetes management practices, the expansion of insulin access programs, and improved rates of diabetes diagnosis.

The short-acting insulin market is set for considerable expansion over the next few years. It is forecast to grow to $14.87 billion in 2030, achieving a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period is driven by factors such as the increasing occurrence of type 2 diabetes, a rise in insulin dependence, the expansion of home-based diabetes care, advancements in insulin delivery technologies, and a growing demand for fast-acting insulin. Key developments expected in the forecast period include an escalating demand for post-meal blood glucose regulation, the increasing utilization of rapid-acting insulin analogues, wider adoption of pre-filled insulin pens, the broadening of intensive insulin therapy approaches, and a stronger focus on precise glycemic management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Market Drivers Are Supporting The Expansion Of The Short-Acting Insulin Market?

The escalating incidence of type 1 diabetes is anticipated to propel the growth of the short-acting insulin market moving forward. Type 1 diabetes, an autoimmune disorder, involves the body’s destruction of insulin-producing cells, thereby necessitating lifelong insulin therapy. The increasing prevalence of Type 1 diabetes stems from genetic factors, environmental triggers, and a rise in autoimmune disorders. Short-acting insulin effectively manages type 1 diabetes by delivering rapid blood sugar control and mirroring the natural insulin response. For example, in December 2023, data from Diabetes Australia, an Australia-based organization focused on raising awareness about diabetes, indicated that roughly 134,000 Australians were living with Type 1 diabetes in 2022, a figure that climbed to 135,423 by 2023. This clearly demonstrates how the increasing prevalence of type 1 diabetes is driving the expansion of the short-acting insulin market.

What Segment Types Make Up The Short-Acting Insulin Market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Which Market Trends Are Creating New Opportunities In The Short-Acting Insulin Market?

Leading companies in the short-acting insulin market are prioritizing innovative offerings, such as interchangeable rapid-acting insulin biologics, to improve glycemic management and offer flexible substitution possibilities for patients with diabetes. An interchangeable rapid-acting insulin biologic refers to an insulin formulation, biologically sourced, that quickly lowers blood glucose levels after meals and has regulatory approval to be swapped for another equivalent insulin product without needing a new prescription, thereby providing adaptability in diabetes care and sustaining consistent glycemic control. As an illustration, in July 2025, Biocon Biologics, a US-based biosimilars company with headquarters in both India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz), distinguishing it as the first and only interchangeable rapid-acting insulin aspart in the United States. Kirsty is a biosimilar to NovoLog (insulin aspart), with clinical and analytical data confirming no significant differences in its safety, effectiveness, purity, or potency. It is provided as a 100 units/mL solution in both a prefilled pen for single-patient subcutaneous use and a multi-dose vial suitable for both subcutaneous and intravenous administration, aimed at enhancing glycemic control in adults and children diagnosed with diabetes mellitus.

Who Are The Key Players Driving Competition In The Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Read the full short-acting insulin market report here:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

How Is The Short-Acting Insulin Market Distributed Across Key Geographic Regions?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Short-Acting Insulin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2026, By The Business Research Company

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Instant Tea Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/instant-tea-premix-global-market-report

Technical Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/technical-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the short-acting insulin market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Short-Acting Insulin Market reach by 2030 starting from 2026 levels?

The short-acting insulin market has shown substantial growth in recent years. It is anticipated to expand from $11.54 billion in 2025 to $12.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This historic growth can be linked to the high prevalence of diabetes, the widespread adoption of insulin therapy, hospital-based diabetes management, the expansion of insulin access programs, and improved diabetes diagnosis rates.

The short-acting insulin market size is anticipated to experience substantial growth over the coming years. By 2030, it is projected to expand to $14.87 billion, achieving a compound annual growth rate (CAGR) of 5.2%. This growth during the forecast period is attributed to several factors, including the rising incidence of type 2 diabetes, increasing insulin dependence, the expansion of home-based diabetes care, developments in insulin delivery technologies, and a growing demand for fast-acting insulin. Significant trends expected during this period involve a rising demand for post-meal blood glucose control, increased use of rapid-acting insulin analogues, the growing adoption of pre-filled insulin pens, the expansion of intensive insulin therapy regimens, and an increased focus on tight glycemic management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Drivers Are Influencing Long-Term Growth In The Short-Acting Insulin Market?

The rising occurrence of type 1 diabetes is projected to stimulate the expansion of the short-acting insulin market moving forward. Type 1 diabetes is an autoimmune disorder where the body destroys cells responsible for insulin production, thereby requiring lifelong insulin therapy. The increasing prevalence of Type 1 diabetes is influenced by genetic factors, environmental triggers, and a rise in autoimmune conditions. Short-acting insulin assists in managing type 1 diabetes by providing swift blood sugar control and mimicking the body’s natural insulin response. For instance, in December 2023, according to Diabetes Australia, an Australia-based organization that aims to increase awareness about diabetes, approximately 134,000 Australians were living with Type 1 diabetes in 2022. This figure increased to 135,423 in 2023. Therefore, the expanding prevalence of type 1 diabetes is fueling the growth of the short-acting insulin market.

Which Segments Are Driving Activity In The Short-Acting Insulin Market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Trends Are Driving The Growth Trajectory Of The Short-Acting Insulin Market?

Leading companies within the short-acting insulin market are concentrating on advanced offerings like interchangeable rapid-acting insulin biologics to improve glycemic management and offer adaptable replacement choices for individuals with diabetes. An interchangeable rapid-acting insulin biologic refers to a biologically derived insulin formulation designed to quickly lower blood glucose levels after meals, approved by regulatory bodies for substitution with an equivalent insulin product without requiring a new prescription, thus providing flexibility in diabetes care and maintaining consistent glycemic control. For example, in July 2025, Biocon Biologics, a US-based biosimilars company with headquarters in both India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz), marking it as the first and only interchangeable rapid-acting insulin aspart available in the United States. Kirsty is a biosimilar to NovoLog (insulin aspart), with clinical and analytical data confirming no significant differences in its safety, efficacy, purity, and potency. It is provided as a 100 units/mL formulation in both a single-patient-use prefilled pen (for subcutaneous administration) and a multi-dose vial (for both subcutaneous and intravenous delivery), aiming to enhance glycemic control in adults and children diagnosed with diabetes mellitus.

Which Major Industry Participants Are Leading The Short-Acting Insulin Market Growth?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Short-Acting Insulin Market?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Short-Acting Insulin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2026, By The Business Research Company

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Instant Tea Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/instant-tea-premix-global-market-report

Technical Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/technical-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the interstitial cystitis drugs market from 2025–2034 with trusted insights from The Business Research Company

How Will The Interstitial Cystitis Drugs Market Size Evolve Between Now And 2029?

The short-acting insulin market has experienced consistent expansion in recent times. It is projected to expand from $11 billion in 2024 to $11.54 billion in 2025, driven by a compound annual growth rate (CAGR) of 4.8%. Factors contributing to this historical growth include an increase in the type 1 diabetes population, a rising geriatric population, a surge in research and development funding, the prevalence of diagnosed instances, and increasing urbanization.

The short-acting insulin market is expected to experience significant expansion in the next few years. It is projected to reach $14.14 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.2%. This growth over the forecast period is attributable to an increase in government initiatives and support, rapid production innovations, the growing adoption of insulin therapy, and the rise of personalized medicine. Prominent trends anticipated during this period encompass advancements in insulin delivery devices and technologies, innovative fast-acting insulin analogs, the development of biosimilars, a transition towards patient-centric care, and improvements in formulation.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Key Drivers Are Powering Growth In The Interstitial Cystitis Drugs Market?

The growing incidence of type 1 diabetes is anticipated to propel the expansion of the short-acting insulin market. Type 1 diabetes is an autoimmune disorder where the body’s cells responsible for producing insulin are destroyed, necessitating lifelong insulin treatment. This increasing occurrence of Type 1 diabetes is influenced by genetic factors, environmental triggers, and a rise in autoimmune conditions. Short-acting insulin aids in managing type 1 diabetes by offering prompt blood sugar regulation and mimicking the body’s natural insulin response. For illustration, Diabetes Australia, an Australia-based organization focused on diabetes awareness, reported that around 134,000 Australians were living with Type 1 diabetes in 2022. This figure subsequently grew to 135,423 in 2023. Thus, the escalating prevalence of type 1 diabetes is a significant force driving the growth of the short-acting insulin market.

How Is The Global Interstitial Cystitis Drugs Market Structured By Key Segments?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Future-Focused Trends Are Anticipated In The Interstitial Cystitis Drugs Market?

Leading companies within the short-acting insulin market are concentrating on developing innovative products like insulin pods, aiming to provide continuous insulin infusion and improve adherence for individuals managing diabetes. An insulin pod is a wearable, tubeless insulin delivery system that facilitates continuous insulin infusion for effective diabetes management. For example, in April 2023, Insulet Corporation, a US-based medical device firm, announced that its groundbreaking basal-only insulin pod, Omnipod GO, designed for adults with type 2 diabetes, received U.S. Food and Drug Administration (FDA) clearance. This tubeless, wearable device offers continuous insulin delivery without requiring a separate controller. Omnipod GO simplifies diabetes management by eliminating daily injections and delivering pre-programmed insulin rates. Its user-friendly design and pharmacy accessibility enhance convenience for both patients and healthcare providers. This introduction highlights Insulet’s ongoing commitment to improving diabetes care through advanced technology.

Which Companies Hold A Competitive Edge In The Interstitial Cystitis Drugs Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Region Is Expected To Lead The Interstitial Cystitis Drugs Market In The Next Few Years?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Browse Through More Reports Similar to the Global Interstitial Cystitis Drugs Market 2025, By The Business Research Company

Insulin Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Smart Insulin Pens Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

Insulin Pens Syringes Pumps And Injectors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-pens-syringes-pumps-and-injectors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Short-Acting Insulin Market By 2029?

The short-acting insulin market size has shown steady expansion in recent years. It is anticipated to increase from $11 billion in 2024 to reach $11.54 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 4.8%. This growth observed in the past can be attributed to factors such as an expanding population of individuals with type 1 diabetes, an aging demographic, a rise in research and development investments, the widespread occurrence of diagnosed cases, and increasing urbanization.

The short-acting insulin market is projected to experience substantial expansion over the upcoming years, reaching “$14.14 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.2%. This anticipated growth during the forecast period can be primarily attributed to several factors: a surge in governmental initiatives and support, rapid advancements in manufacturing processes, the growing acceptance of insulin therapy, and the emergence of personalized medicine. Key trends anticipated during this period encompass progress in insulin delivery devices and associated technologies, the introduction of innovative fast-acting insulin analogs, the continuous development of biosimilars, a noticeable shift towards patient-focused care, and improvements in formulation techniques.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Major Market Drivers Are Shaping The Future Of The Short-Acting Insulin Market?

The growing occurrence of Type 1 diabetes is projected to boost the expansion of the short-acting insulin market in the future. Type 1 diabetes represents an autoimmune ailment characterized by the immune system attacking insulin-generating cells, necessitating continuous insulin treatment. The increasing incidence of Type 1 diabetes stems from genetic predispositions, environmental factors, and a rise in autoimmune conditions. Short-acting insulin assists in managing Type 1 diabetes by offering prompt regulation of blood sugar levels and emulating the body’s natural insulin action. As an illustration, data from Diabetes Australia, an Australian organization dedicated to diabetes awareness, indicated that in 2022, around 134,000 Australians had Type 1 diabetes. This number saw an increase, reaching 135,423 in 2023. Consequently, the escalating prevalence of Type 1 diabetes is propelling the growth of the short-acting insulin market.

Which Key Segments Fueling The Short-Acting Insulin Market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Are The Major Trends Driving The Growth Of The Short-Acting Insulin Market?

Major companies active in the short-acting insulin market are focusing on innovative products, such as insulin pods, to provide continuous insulin infusion and adherence for individuals with diabetes. An insulin pod is defined as a tubeless, wearable insulin delivery system that offers continuous insulin infusion for diabetes management. For instance, in April 2023, Insulet Corporation, a US-based medical device company, announced U.S. Food and Drug Administration (FDA) clearance for Omnipod GO, a groundbreaking basal-only insulin pod specifically designed for adults with type 2 diabetes. This tubeless, wearable device ensures continuous insulin delivery without requiring a separate controller. Omnipod GO simplifies diabetes management by eliminating daily injections and providing pre-programmed insulin rates. With its user-friendly design and pharmacy accessibility, it enhances convenience for both patients and healthcare providers. This launch reinforces Insulet’s commitment to improving diabetes care through innovative technology.

Which Key Market Players Are Investing In Expansion And Innovation Of Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Short-Acting Insulin Market?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2025, By The Business Research Company

Insulin Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Smart Insulin Pens Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

Insulin Pens Syringes Pumps And Injectors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-pens-syringes-pumps-and-injectors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model